Drug Profile


Alternative Names: anti-B7.1 Mab + anti-B7.2 Mab

Latest Information Update: 13 Sep 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Innogenetics
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 13 Sep 2001 Discontinued-Preclinical for Transplant rejection in Netherlands (Unknown route)
  • 05 Oct 2000 Innogentics has the intention to partner with biopharmceutical companies for the programme
  • 15 Jan 1999 Preclinical development for Transplant rejection in Netherlands (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top